Correction: Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells-an in‑vitro study

Affiliations

¹ Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU, Munich, Germany. teresafbrunner@gmail.com.
² Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU, Munich, Germany.
³ Department of Otolaryngology, Head and Neck Surgery, University Hospital, LMU, Munich, Germany.
⁴ Terraplasma GmbH, Garching, Germany.
⁵ Department of Otolaryngology, Head and Neck Surgery, University Hospital, EKU, Tubingen, Germany.
⁶ Department of ENT/Head and Neck Surgery, Asklepios Hospital, Bad Tolz, Germany.
⁷ HNO Munchen Nord, Munich, Germany.

Published Erratum

Teresa F Brunner et al. Head Face Med. 2023.

. 2023 Aug 18;19(1):35.

doi: 10.1186/s13005-023-00386-x.

¹ Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU, Munich, Germany. teresafbrunner@gmail.com.
² Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU, Munich, Germany.
³ Department of Otolaryngology, Head and Neck Surgery, University Hospital, LMU, Munich, Germany.
⁴ Terraplasma GmbH, Garching, Germany.
⁵ Department of Otolaryngology, Head and Neck Surgery, University Hospital, EKU, Tubingen, Germany.
⁶ Department of ENT/Head and Neck Surgery, Asklepios Hospital, Bad Tolz, Germany.
⁷ HNO Munchen Nord, Munich, Germany.

No abstract available

Erratum for

Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells-an in-vitro study.
Brunner TF, Probst FA, Troeltzsch M, Schwenk-Zieger S, Zimmermann JL, Morfill G, Becker S, Harréus U, Welz C. Brunner TF, et al. Head Face Med. 2022 Jun 29;18(1):21. doi: 10.1186/s13005-022-00322-5. Head Face Med. 2022. PMID: 35768853 Free PMC article. Review.

1. Brunner TF, Probst FA, Troeltzsch M, et al. Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study. Head Face Med. 2022;18:21. doi: 10.1186/s13005-022-00322-5. - DOI - PMC - PubMed